Resistance to ADT may be caused by several mechanisms linked to androgen signaling, including androgen production within the tumor itself or by the adrenal glands, AR gene amplification or overexpression, the presence of AR mutations, and the development of constitutively active AR splice variants [210]. The gene discussed is AR; the disease is neoplasm.